ECSP066553A - Formas de administración masticables, no comprimidas dosificadas individualmente. - Google Patents

Formas de administración masticables, no comprimidas dosificadas individualmente.

Info

Publication number
ECSP066553A
ECSP066553A EC2006006553A ECSP066553A ECSP066553A EC SP066553 A ECSP066553 A EC SP066553A EC 2006006553 A EC2006006553 A EC 2006006553A EC SP066553 A ECSP066553 A EC SP066553A EC SP066553 A ECSP066553 A EC SP066553A
Authority
EC
Ecuador
Prior art keywords
administration forms
individually dosed
compressed
masticable
dosed administration
Prior art date
Application number
EC2006006553A
Other languages
English (en)
Spanish (es)
Inventor
Vidal Jose Luis Fabregas
Carbonell Antoni Masso
Gonzalez Nuria Garcia
Coll Pere Guiro
Original Assignee
Almirall Prodesfarma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34610359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066553(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Prodesfarma Sa filed Critical Almirall Prodesfarma Sa
Publication of ECSP066553A publication Critical patent/ECSP066553A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EC2006006553A 2003-11-10 2006-05-08 Formas de administración masticables, no comprimidas dosificadas individualmente. ECSP066553A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200302612A ES2235626B1 (es) 2003-11-10 2003-11-10 Formas de administracion masticables, no comprimidas dosificadas individualmente.

Publications (1)

Publication Number Publication Date
ECSP066553A true ECSP066553A (es) 2006-12-20

Family

ID=34610359

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006553A ECSP066553A (es) 2003-11-10 2006-05-08 Formas de administración masticables, no comprimidas dosificadas individualmente.

Country Status (25)

Country Link
US (1) US20070134318A1 (enExample)
EP (1) EP1682097B1 (enExample)
JP (1) JP4879021B2 (enExample)
KR (1) KR20060116821A (enExample)
CN (1) CN1878542A (enExample)
AR (1) AR048050A1 (enExample)
AT (1) ATE492270T1 (enExample)
AU (1) AU2004290517B2 (enExample)
BR (1) BRPI0416215A (enExample)
CA (1) CA2548615A1 (enExample)
CO (1) CO5690531A2 (enExample)
DE (1) DE602004030706D1 (enExample)
EC (1) ECSP066553A (enExample)
ES (2) ES2235626B1 (enExample)
IL (1) IL175285A (enExample)
MY (1) MY143793A (enExample)
NO (1) NO20062723L (enExample)
NZ (1) NZ546375A (enExample)
PE (1) PE20050488A1 (enExample)
RU (1) RU2369379C2 (enExample)
TW (1) TW200526266A (enExample)
UA (1) UA90253C2 (enExample)
UY (1) UY28586A1 (enExample)
WO (2) WO2005048975A1 (enExample)
ZA (1) ZA200602416B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089559A1 (en) 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
ES2420960T3 (es) 2006-08-23 2013-08-28 Valeant Pharmaceuticals International Derivados de 4-(N-azacicloalquil)anilidas como moduladores de los canales de potasio
AU2007325629A1 (en) 2006-11-28 2008-06-05 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
WO2009002084A2 (en) * 2007-06-27 2008-12-31 Hanmi Pharm. Co., Ltd. Method for preparing rapidly disintegrating formulation for oral administration and apparatus for preparing and packing the same
IL187159A0 (en) 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
EP2323735A1 (en) 2008-07-29 2011-05-25 Alcobra Ltd. Substituted pyridoxine-lactam carboxylate salts
EP2238976B1 (en) * 2009-04-03 2012-06-27 Hexal AG Oral films comprising 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro- 1H-quinolin-2-one base or salts or hydrates thereof
CA2766107A1 (en) 2009-06-25 2010-12-29 Alcobra Ltd. A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition
EA021368B1 (ru) * 2011-06-21 2015-06-30 Общество С Ограниченной Ответственностью "Консорциум-Пик" Препарат кардиопротекторного действия
CN105911057B (zh) * 2016-06-22 2018-10-19 扬州一洋制药有限公司 一种铝镁加混悬液的质量控制方法
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
PH12022551110A1 (en) 2019-11-08 2024-02-26 Xenon Pharmaceuticals Inc Methods of treating depressive disorders
JP2024508660A (ja) 2021-02-09 2024-02-28 ゼノン・ファーマシューティカルズ・インコーポレイテッド 快感消失の治療に使用するための電位依存性カリウムチャネル開口薬
CN113425694A (zh) * 2021-07-02 2021-09-24 杭州蚕宝生物技术有限公司 一种石斛生物碱口腔崩解片剂及其制备方法
US12053484B2 (en) 2021-10-29 2024-08-06 Medicated Chews, Llc Simethicone chewable composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5645411A (en) * 1979-09-20 1981-04-25 Taiho Yakuhin Kogyo Kk Poultice
FR2515035A1 (fr) * 1981-10-26 1983-04-29 Rhone Poulenc Sante Nouvelle forme galenique solide pour administration par voie orale et son procede de fabrication
EP0409432A3 (en) * 1989-07-20 1991-12-11 Warner-Lambert Company Confectionery delivery system
US5433951A (en) * 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
JPH08319232A (ja) * 1995-03-22 1996-12-03 Takeda Chem Ind Ltd 粉粒状組成物
JPH0912463A (ja) * 1995-06-23 1997-01-14 Fujisawa Pharmaceut Co Ltd 口中咀嚼用製剤
US20030216303A1 (en) * 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
US6171615B1 (en) * 1998-07-06 2001-01-09 Gattefoss{acute over (e)} Sustained release theophylline formulations, excipient systems and methods of production
US6060078A (en) * 1998-09-28 2000-05-09 Sae Han Pharm Co., Ltd. Chewable tablet and process for preparation thereof
US6652880B1 (en) * 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
EP2298284A3 (en) * 2001-02-14 2013-12-18 GW Pharma Limited Mucoadhesive pharmaceutical formulations
US6692771B2 (en) * 2001-02-23 2004-02-17 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
RU2197094C1 (ru) * 2001-12-26 2003-01-27 Ставрулов Игорь Анатольевич Жевательная резинка

Also Published As

Publication number Publication date
CO5690531A2 (es) 2006-10-31
ATE492270T1 (de) 2011-01-15
AU2004290517A1 (en) 2005-06-02
WO2005048974A2 (en) 2005-06-02
AU2004290517B2 (en) 2010-05-27
EP1682097A2 (en) 2006-07-26
WO2005048974A3 (en) 2006-02-23
ZA200602416B (en) 2009-06-24
AR048050A1 (es) 2006-03-29
IL175285A (en) 2011-04-28
NZ546375A (en) 2009-11-27
EP1682097B1 (en) 2010-12-22
ES2235626A1 (es) 2005-07-01
CN1878542A (zh) 2006-12-13
PE20050488A1 (es) 2005-08-24
ES2358332T3 (es) 2011-05-09
JP4879021B2 (ja) 2012-02-15
MY143793A (en) 2011-07-15
TW200526266A (en) 2005-08-16
BRPI0416215A (pt) 2006-12-26
US20070134318A1 (en) 2007-06-14
UY28586A1 (es) 2005-05-31
NO20062723L (no) 2006-06-12
IL175285A0 (en) 2006-09-05
UA90253C2 (ru) 2010-04-26
RU2006120087A (ru) 2007-12-27
RU2369379C2 (ru) 2009-10-10
KR20060116821A (ko) 2006-11-15
DE602004030706D1 (de) 2011-02-03
WO2005048975A1 (en) 2005-06-02
CA2548615A1 (en) 2005-06-02
ES2235626B1 (es) 2006-11-01
JP2007510690A (ja) 2007-04-26

Similar Documents

Publication Publication Date Title
ECSP066553A (es) Formas de administración masticables, no comprimidas dosificadas individualmente.
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
AR049083A1 (es) Proceso para la preparacion de una forma de dosificacion solida a prueba de abuso
CL2008002407A1 (es) Forma de dosificacion oral que comprende al menos un agente activo de nicotina, al menos un material bioadhesivo capaz de formar un enlace de hidrogeno con el agente activo de nicotina, y al menos un agente de impacto sensorial que se libere rapidamente; y su uso para proporcionar alivio rapido de las ansias de nicotina (div. sol. 1825-04).
AR058175A1 (es) Composiciones farmaceuticas solidas que contienen pregabalina
AR109263A2 (es) Composición que comprende moxidectina
AR046510A1 (es) Composicion de un antagonista de vegf y un agente anti-proliferativo
HRP20060147B1 (hr) Terapijski sustav s kontroliranim otpuštanjem za nazalnu primjenu
MXPA05007643A (es) Metodo para producir una forma farmaceutica oral con desintegracion inmediata y liberacion de ingrediente activo.
CL2008000893A1 (es) Composición para el cuidado bucal que comprende una cantidad efectiva de un aminoácido básico y un agente antibacteriano; uso en el tratamiento antibacteriano de la cavidad bucal.
PA8509001A1 (es) Forma de dosificacion de farmacos accionada por un hidrogel
AR019690A1 (es) Formulacion farmaceutica para aerosoles con dos o mas sustancias activas
AR029562A1 (es) Forma de administracion desintegrable ra pidamente para la liberacion de principios activos en la cavidad bucal o en otras cavidades corporales, proceso de fabricacion y usos
AR044131A1 (es) Peliculas consumibles oralmente de disolucion rapida que contienen un almidon modificado para la mejora de la resistencia al calor y a la humedad
AR071850A1 (es) Gomas de mascar en forma de tableta
AR030884A1 (es) Formulaciones dentifricas anhidras para la liberacion de ingredientes incompatibles y procedimiento para reducir la hipersensibilidad dentinal y remineralizar las superficies dentinales expuestas y los tubulos dentinales abiertos
UY26529A1 (es) Composición de gliburida.
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
PA8559501A1 (es) Formulaciones farmaceuticas de 5,7,14-triazatetraciclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaeno
ECSP034826A (es) Método para fabricar una composición farmacéutica de dosis baja
CL2004000899A1 (es) Composicion farmaceutica que contiene la sal sodica de telmisartan y un agente diuretico y procedimiento de preparacion.
CO6640264A2 (es) Combinación de gránulos cargados activos con activos adicionales
PA8548301A1 (es) Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion
ATE476997T1 (de) Zusammensetzung und dosierform mit einer festen oder halbfesten matrix
CL2004001843A1 (es) Combinacion de (a) al menos un derivado 2,5-dihidrobencenosulfonico, como el dobeilato calcico, etamsilato y persilato, y (b) al menos un modulador de los canales de potasio, composicion farmaceutica que la contiene y uso como medicamento en profilax